In vivo post-transcriptional gene silencing of α-1 antitrypsin by adeno-associated virus vectors expressing siRNA

Laboratory Investigation

Volumn 87, Issue 9, 2007, Pages 893-902

  Cruz, Pedro E ^a,b   Mueller, Christian ^a,b   Cossette, Travis L ^b   Golant, Alexandra ^c   Tang, Qiushi ^a,b   Beattie, Stuart G ^a,b   Brantly, Mark ^a   Campbell Thompson, Martha ^a   Blomenkamp, Keith S ^d   Teckman, Jeffrey H ^d   Flotte, Terence R ^a,b,e,f  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

1 antitrypsin; PI; rAAV; siRNA; Z

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; RECOMBINANT ALPHA 1 ANTITRYPSIN; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HISTOCHEMISTRY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; RNA SEQUENCE; TRANSGENIC MOUSE; VIRUS CAPSID; VIRUS RECOMBINANT;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; CELL LINE, TUMOR; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE THERAPY; GENETIC VECTORS; HEPATOCYTES; HUMANS; MICE; MICE, TRANSGENIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 34547943486     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700629     Document Type: Article

References (45)

1. Crystal RG. The alpha 1-antitrypsin gene and its deficiency states. Trends Genet 1989;5:411-417.
2. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990;85:1343-1352.
3. Birrer P, McElvaney NG, Chang-Stroman LM, et al. Alpha 1-antitrypsin deficiency and liver disease. J Inherit Metab Dis 1991;14:512-525.
4. Perlmutter DH. Alpha-1-antitrypsin deficiency: biochemistry and clinical manifestations. Ann Med 1996;28:385-394.
5. Teckman JH, Qu D, Perlmutter DH. Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Hepatology 1996;24:1504-1516.
6. Geller SA, Nichols WS, Dycaico MJ, et al. Histopathology of alpha 1-antitrypsin liver disease in a transgenic mouse model. Hepatology 1990;12:40-47.
7. Lomas DA, Evans DL, Stone SR, et al. Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. Biochemistry 1993;32:500-508.
8. Lomas DA. Loop-sheet polymerization: the structural basis of Z alpha 1-antitrypsin accumulation in the liver. Clin Sci Lond 1994;86:489-495.
9. Lomas DA. Loop-sheet polymerization: the mechanism of alpha1-antitrypsin deficiency. Respir Med 2000;94(Suppl C):S3-S6.
10. Lomas DA, Mahadeva R. Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 2002;110:1585-1590.
11. Lomas DA, Lourbakos A, Cumming SA, et al. Hypersensitive mousetraps, alpha1-antitrypsin deficiency and dementia. Biochem Soc Trans 2002;30:89-92.
12. Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency, 4: molecular pathophysiology. Thorax 2004;59:529-535.
13. Lomas DA, Belorgey D, Mallya M, et al. Polymerisation underlies alpha1-antitrypsin deficiency, dementia and other serpinopathies. Front Biosci 2004;9:2873-2891.
14. Lomas DA. Molecular mousetraps, alpha1-antitrypsin deficiency and the serpinopathies. Clin Med 2005;5:249-257.
15. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency - a model for conformational diseases. N Engl J Med 2002;346:45-53.
16. Song S, Morgan M, Ellis T, et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998;95:14384-14388.
17. Song S, Embury J, Laipis PJ, et al. Stable therapeutic serum levels of human alpha-1 antitrypsin AAT; after portal vein injection of recombinant adeno-associated virus rAAV; vectors. Gene Therapy 2001;8:1299-1306.
18. Song S, Scott-Jorgensen M, Wang J, et al. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin rAAV-SERPINA1; vectors in a nonhuman primate model: safety and immunologic aspects. Mol Ther 2002;6:329-335.
19. Conlon TJ, Cossette T, Erger K, et al. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector. Mol Ther 2005;12:867-875.
20. Lu Y, Choi YK, Campbell-Thompson M, et al. Therapeutic level of functional human alpha 1 antitrypsin hAAT; secreted from murine muscle transduced by adeno-associated virus rAAV1; vector. J Gene Med 2006;8:730-735.
21. Flotte TR, Brantly ML, Spencer LT, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin rAAV2-CB-hAAT; gene vector to AAT-deficient adults. Hum Gene Ther 2004;15:93-128.
22. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alpha1;antitrypsin AAT; vector in AAT-deficient adults. Hum Gene Ther 2006;17:1177-1186.
23. Zern MA, Ozaki I, Duan L, et al. A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Therapy 1999;6:114-120.
24. Xiao W, Berta SC, Lu MM, et al. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 1998;72:10222-10226.
25. Chen SJ, Tazelaar J, Moscioni AD, et al. In vivo selection of hepatocytes transduced with adeno-associated viral vectors. Mol Ther 2000;1:414-422.
26. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005;5:285-297.
27. Gao GP, Lu Y, Sun X, et al. High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J Virol 2006;80:6192-6194.
28. Grimm D, Pandey K, Nakai HS, et al. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 2006;80:426-439.
29. Elbashir SM, Martinez J, Patkaniowska A, et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001;20:6877-6888.
30. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
31. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200.
32. Zolotukhin S, Potter M, Zolotukhin I, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002;28:158-167.
33. Loiler SA, Conlon TJ, Song S, et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Therapy 2003;10:1551-1558.
34. Carlson JA, Rogers BB, Sifers RN, et al. Multiple tissues express alpha 1-antitrypsin in transgenic mice and man. J Clin Invest 1988;82:26-36.
35. Carlson JA, Rogers BB, Sifers RN, et al. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest 1989;83:1183-1190.
36. Dycaico MJ, Grant SG, Felts K, et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. Science 1988;242:1409-1412.
37. Dycaico MJ, Felts K, Nichols SW, et al. Neonatal growth delay in alpha-1-antitrypsin disease. Influence of genetic background. Mol Biol Med 1989;6:137-141.
38. An JK, Blomenkamp K, Lindblad D, et al. Quantitative isolation of alphalAT mutant Z protein polymers from human and mouse livers and the effect of heat. Hepatology 2005;41:160-167.
39. Rudnick DA, Liao Y, An JK, et al. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Hepatology 2004;39:1048-1055.
40. Rudnick DA, Shikapwashya O, Blomenkamp K, et al. Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. Hepatology 2006;44:976-982.
41. Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002;99:11854-11859.
42. Grimm D, Zhou S, Nakai H, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003;102:2412-2419.
43. Miao CH, Nakai H, Thompson AR, et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol 2000;74:3793-3803.
44. Nakai H, Thomas CE, Storm TA, et al. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol 2002;76:11343-11349.
45. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-541.